Abstract
Recent trials, and meta-analyses, have cast further doubt on the clinically desirable and safe range for increasing haemoglobin in chronic kidney disease using erythropoiesis-stimulating agents. In this article, I review the current dilemmas we face, suggest key clinical and biological research priorities, and conclude that we need to be brave enough to admit our present shortcomings, and then perhaps adopt a more patient-focused, individualized approach to anaemia management.
Full Text 
Sign-in/Register to access full text options
Sign-in/Register to access full text options 
Paper version not known
Talk to us
Join us for a 30 min session where you can share your feedback and ask us any queries you have
Schedule a call
